Connection
Lisa Bero to Hydroxymethylglutaryl-CoA Reductase Inhibitors
This is a "connection" page, showing publications Lisa Bero has written about Hydroxymethylglutaryl-CoA Reductase Inhibitors.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.731 |
|
|
|
-
de Rezende LFM, Rey-L?pez JP, de S? TH, Chartres N, Fabbri A, Powell L, Stamatakis E, Bero L. Reporting bias in the literature on the associations of health-related behaviors and statins with cardiovascular disease and all-cause mortality. PLoS Biol. 2018 06; 16(6):e2005761.
Score: 0.459
-
Anglemyer AT, Krauth D, Bero L. Industry sponsorship and publication bias among animal studies evaluating the effects of statins on atherosclerosis and bone outcomes: a meta-analysis. BMC Med Res Methodol. 2015 Mar 06; 15:12.
Score: 0.365
-
Bero L. Bias related to funding source in statin trials. BMJ. 2014 Oct 03; 349:g5949.
Score: 0.355
-
Krauth D, Anglemyer A, Philipps R, Bero L. Nonindustry-sponsored preclinical studies on statins yield greater efficacy estimates than industry-sponsored studies: a meta-analysis. PLoS Biol. 2014 Jan; 12(1):e1001770.
Score: 0.338
-
Bero L, Oostvogel F, Bacchetti P, Lee K. Factors associated with findings of published trials of drug-drug comparisons: why some statins appear more efficacious than others. PLoS Med. 2007 Jun; 4(6):e184.
Score: 0.213